Healthcare Global Enterprises Sees 11% Profit Dip Amid Growth Investments

Healthcare Global Enterprises reports an 11% dip in profit after tax, down to Rs 16 crore in Q2 of FY26, due to higher depreciation and interest from growth investments. Despite this, revenue increased by 17% to Rs 647 crore. The company focuses on advanced diagnostics and targeted therapies.

Cancer-focused healthcare provider, Healthcare Global Enterprises, reported an 11% decrease in profit after tax, reaching Rs 16 crore in the September quarter of FY26.

The Bengaluru-based company had recorded a Rs 18 crore profit in the same quarter last fiscal, citing higher depreciation and interest expenses from growth strategies and acquisitions.

Despite the dip in profit, the firm saw a 17% year-on-year increase in revenue, totaling Rs 647 crore for Q2. HCG is investing in advanced molecular diagnostics and organoid-based platforms to advance drug discovery tailored to Indian genetic diversity.

(With inputs from agencies.)